According to the earnings report, aflibercept sales in the United States increased 7% to $1.02 billion versus third quarter 2017 results.
Yesterday, Regeneron posted positive third quarter earnings results for 2018 that show a steady increase in sales for aflibercept (Eylea), a treatment for wet age-related macular degeneration (AMD).
According to the earnings report, aflibercept sales in the United States increased 7% to $1.02 billion versus third quarter 2017 results. Comparatively, in the second quarter in 2018, the drug earned $992 million in the United States. Aflibercept, now deemed a “blockbuster eye therapy,” earned developer Regeneron $1.68 billion globally, an 11% increase compared with third quarter 2017 results.
“Regeneron continues to grow and diversify our business, while continuing to deliver very strong financial results. In addition to Eylea reaching over $1 billion in quarterly US net sales, we also made significant progress with Dupixent, a key driver of future growth,” said Leonard Schleifer, MD, PhD, president and CEO of Regeneron.
Notably, however, the success of aflibercept comes before biosimilars of the drug make their way to market. Momenta Pharmaceuticals, together with Mylan, has been in the process of developing M710, a proposed biosimilar referencing Eylea. In January 2018, it was announced that the proposed biosimilar would enter a pivotal clinical trial in patients with diabetic macular edema.
Similarly, South Korea-based drug maker Altogen announced intentions earlier this year to file an Investigational New Drug application for its proposed biosimilar aflibercept, ALT-L9, in 2018 after data were released from a study that demonstrated similarity between the potential biosimilar and the reference in preclinical studies.
Biosimilars are not the only potential competitor to Eylea, however, as there are also 2 new reference products being developed for overlapping treatments. Novartis’ phase 3 brolucizumab for the treatment of AMD, and Roche’s phase 2 faricimab for the treatment of diabetic macular edema are both expected to enter the market soon, and bevacizumab, used off-label, is also widely used in treating eye disorders.
Regeneron is preparing for increased competition in the space by seeking further indications and updated dosing schedules. Currently, the FDA is scheduled to reach a decision on the drug’s use in diabetic retinopathy by May 13, 2019.
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.